Abstract:Although several cell-based therapies have received FDA approval, and others are showing promising results, scalable, and quality-driven reproducible manufacturing of therapeutic cells at a lower cost remains challenging. Challenges include starting material and patient variability, limited understanding of manufacturing process parameter effects on quality, complex supply chain logistics, and lack of predictive, well-understood product quality attributes. These issues can manifest as increased production costs, longer production times, greater batch-to-batch variability, and lower overall yield of viable, high-quality cells. The lack of data-driven insights and decision-making in cell manufacturing and delivery is an underlying commonality behind all these problems. Data collection and analytics from discovery, preclinical and clinical research, process development, and product manufacturing have not been sufficiently utilized to develop a "systems" understanding and identify actionable controls. Experience from other industries shows that data science and analytics can drive technological innovations and manufacturing optimization, leading to improved consistency, reduced risk, and lower cost. The cell therapy manufacturing industry will benefit from implementing data science tools, such as data-driven modeling, data management and mining, AI, and machine learning. The integration of data-driven predictive capabilities into cell therapy manufacturing, such as predicting product quality and clinical outcomes based on manufacturing data, or ensuring robustness and reliability using data-driven supply-chain modeling could enable more precise and efficient production processes and lead to better patient access and outcomes. In this review, we introduce some of the relevant computational and data science tools and how they are being or can be implemented in the cell therapy manufacturing workflow. We also identify areas where innovative approaches are required to address challenges and opportunities specific to the cell therapy industry. We conclude that interfacing data science throughout a cell therapy product lifecycle, developing data-driven manufacturing workflow, designing better data collection tools and algorithms, using data analytics and AI-based methods to better understand critical quality attributes and critical-process parameters, and training the appropriate workforce will be critical for overcoming current industry and regulatory barriers and accelerating clinical translation.

Using data analytics to accelerate biopharmaceutical process scale-up

Development and Qualification of a Scale-Down Mammalian Cell Culture Model and Application in Design Space Development by Definitive Screening Design

Productive CHO cell lines selection in biopharm process development through machine learning on metabolomic dynamics

Predictive modeling for cell culture in commercial manufacturing of biotherapeutics

1H NMR-based Process Understanding and Biochemical Marker Identification Methodology for Monitoring CHO Cell Culture Process During Commercial-Scale Manufacturing

A perspective‐driven and technical evaluation of machine learning in bioreactor scale‐up: A case‐study for potential model developments

Interfacing data science with cell therapy manufacturing: where we are and where we need to be

Allogeneic cell therapy bioprocess economics and optimization: Single‐use cell expansion technologies

Developing a Computational Framework To Advance Bioprocess Scale-Up

A Two-Phase Approach Optimizing Productivity for a mAb-producing CHO Cell Culture Process Using Dynamic Response Surface Methodology Models

A Data-Driven Approach for Leveraging Inline and Offline Data to Determine the Causes of Monoclonal Antibody Productivity Reduction in the Commercial-Scale Cell Culture Process

Cell culture process metabolomics together with multivariate data analysis tools opens new routes for bioprocess development and glycosylation prediction

Enhancing early-stage cell culture process development efficiency using an integrated approach of high-throughput miniaturized bioreactors and definitive screening design

Next-generation cell line selection methodology leveraging data lakes, natural language generation and advanced data analytics

Scale-Up Technologies for the Manufacture of Adherent Cells

[New Opportunities and Challenges for Hybrid Data and Model Driven Bioprocess Optimization and Scale-Up].

Robust factor selection in early cell culture process development for the production of a biosimilar monoclonal antibody

High-Throughput Raman Spectroscopy Combined with Innovate Data Analysis Workflow to Enhance Biopharmaceutical Process Development

Model uncertainty-based evaluation of process strategies during scale-up of biopharmaceutical processes

A hierarchical model combining process and Raman spectroscopic data for real-time monitoring of cell culture process

Data Augmentation to Support Biopharmaceutical Process Development through Digital Models—A Proof of Concept